CellProtect (ex vivo expanded and activated autologous natural killer cells) - Avaris, XNK Therap
Sarclisa (isatuximab-irfc) - Sanofi
https://www.prnewswire.com/news-releases/xnk-therapeutics-reports-first-patient-treated-in-phase-ii-study-in-multiple-myeloma-301508734.html
 
Mar 23, 2022
 
Prev Next